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Cannabidivarin (CBDV) and cannabidiol (CBD) have recently emerged among
cannabinoids for their potential antiepileptic properties, as shown in several animal
models. We report the case of a patient affected by symptomatic partial epilepsy who
used cannabis as self-medication after the failure of countless pharmacological/surgical
treatments. Clinical and video electroencephalogram (EEG) evaluations were periodi-
cally performed, and the serum levels of CBDV, CBD, and D9-tetrahydrocannabinol
were repeatedly measured. After cannabis administration, a dramatic clinical
improvement, in terms of both decrease in seizure frequency and recovery of cognitive
functions, was observed, which might parallel high CBDV plasma concentrations. To
widen the spectrum of CBDV possible mechanisms of action, electrophysiological
methods were applied to investigate whether it could exert some effects on c-amino-
butyric acid (GABA)A receptors. Our experiments showed that, in human hippocam-
pal tissues of four patients affected by drug-resistant temporal lobe epilepsy (TLE)
transplanted in Xenopus oocytes, there is decrease of current rundown (i.e., reduction
of use-dependent GABAA current) after prolonged exposure to CBDV. This result has
been confirmed using a single case of Rasmussen encephalitis (RE). Our patient’s elec-
troclinical improvement supports the hypothesis that cannabis could actually repre-
sent an effective, well-tolerated antiepileptic drug. Moreover, the experimental data
suggest that CBDV may greatly contribute to cannabis anticonvulsant effect through
its possible GABAergic action.
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The potential role of cannabis in treating several diseases,
including epilepsy, has been known for centuries.1,2 On the
basis of in vitro and in vivo studies, phytocannabinoids
other than the well-known D9-tetrahydrocannabinol (D9-
THC) are thought to have a major anticonvulsant effect, and
in particular cannabidiol (CBD) has received great attention
in the scientific community and media.3–5 Its propyl ana-
logue, cannabidivarin (CBDV), has been recently proposed
to have an antiepileptic action in animal models.6 However,
data from well-designed clinical trials for both compounds
are still lacking.7 We report the case of a patient affected by
drug-resistant focal epilepsy treated with homemade canna-
bis-containing infusions who underwent clinical, video
electroencephalogram (EEG) and laboratory monitoring.
Considering the patient’s global improvement and the labo-
ratory findings suggesting a possible beneficial effect of
CBDV, we used the technique of membrane microtrans-
plantation from brain tissues to Xenopus laevis oocytes8 to
investigate whether CBDV may affect c-aminobutyric acid
(GABA)-ergic transmission.
Case Report
Clinical, EEG, and neuroimaging findings
We report the case of a 19-year-old boy referred to our
Epilepsy Centre for a symptomatic, probably immune-
mediated partial epilepsy begun at the age of 5. His medical
history was characterized by progressive unilateral neuro-
logical deficits, namely, right hemiparesis with dystonia
and motor aphasia, and recurrent partial seizures with
heterogeneous subjective manifestations, right motor signs,
and speech and consciousness impairment. EEG recordings
showed abundant epileptiform activity on the left cen-
trotemporal regions. Magnetic resonance imaging (MRI)
scans documented a lesion involving left putamen, external
capsule, and insula along with atrophy of the head of the
ipsilateral caudate nucleus, first interpreted as a perinatal
hypoxic/ischemic lesion (Fig. 1). Cardiological evaluation,
autoantibody screening (including anti-Hu, Yo, Ri, Ma2,
CV2, amphiphysin, N-methyl-D-aspartate receptor
[NMDAR], voltage-gated potassium channel receptor
[VGKCR], GABAB- receptor [GABAB-R], and a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor
[AMPAR] antibodies), and cerebrospinal fluid analyses
were normal; only homozygous prothrombin G20210A
mutation was detected. After the failure of all available
antiepileptic drugs (used in several associations) and the
recurrence of convulsive status epilepticus requiring inten-
sive care unit management, vagus nerve stimulation and sur-
gical treatments (specifically, removal of left insula,
anterior temporal lobe, hippocampus, and amygdala) were
unsuccessfully attempted. Although histological findings
were rather nonspecific, age at onset, clinical and radiologi-
cal features (unilateral neurological deficits, unilateral sei-
zure onset, and basal ganglia involvement), and the
dramatic evolution were highly suggestive of a focal variant
of Rasmussen encephalitis (RE) primarily involving the
temporal lobe; therefore, oral and intravenous steroids were
administered without improvement (for more details, see
the Supporting materials section).
Empirical use of cannabis
In January 2014, the patient was experiencing dozens of
seizures a day, characterized by right perioral myoclonia
followed by stiffening of the right arm and increased diffi-
culty in word reaching, with prolonged postictal weakness.
Interictal video EEG showed a subcontinuous paroxysmal
activity involving the left hemisphere, especially frontocen-
tral and anterior temporal regions (Fig. 1). At that time, his
parents decided to try cannabis and started giving him
homemade oral infusions obtained by simmering 300–
400 mg of cannabis inflorescence in 250 ml of milk twice a
day. His previous therapy (topiramate 300 mg/day, leve-
tiracetam 4,000 mg/day, carbamazepine 800 mg/day, and
clonazepam 4 mg/day) was unchanged.
Follow-up and outcome
Seizures decreased in frequency soon after the treat-
ment was started. During the following months, different
strains of cannabis were used with variable clinical
Figure 1.
(A) EEG recording performed before the introduction of cannabis: the tracing shows a subcontinuous paroxysmal epileptiform activity
characterized by discharges of spikes in the left hemisphere with rapid contralateral transmission, followed by a brief voltage attenuation
on the left frontocentral and anterior temporal regions, and then by a pseudoperiodic slow spike-and-wave activity propagating over the
midposterior temporal areas. The clinical correlate consisted of a seizure characterized by intense right perioral myoclonus (*), followed
by ipsilateral tonic deviation of the mouth (●), dystonic posturing of the right limbs (♦), and partial consciousness impairment ( ).The
neurological examination showed severe ideomotor slowing and an evident worsening of the preexistent aphasia, with increased difficulty
in verbal comprehension and word reaching. (B) EEG recording performed 1 year after the introduction of cannabis: the tracing shows
diffuse discharges of spikes, clinically associated with isolated perioral myoclonus (*), and focal theta-delta activity intermingled with
spikes and spike-and-waves located on the frontal and anterior and middle temporal regions. An improvement in cognitive and, more
specifically, language functions was observed. (C) MRI scan (FLAIR and IR sequences). On the left: MRI scan before surgery, showing the
presence of a lesion involving the left insula with concomitant slight hyperintensity and bulging of the mesial temporal area and atrophy of
the head of the ipsilateral caudate nucleus. On the right: MRI scan after left temporal lobectomy, showing diffuse white matter alterations
and left lateral ventricle dilatation.
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Figure 2.
(A) Cannabinoids serum levels and electroclinical correlations. B: baseline, defined as the coexistence of subcontinuous motor seizures
(right perioral myoclonus, ipsilateral tonic deviation of the mouth, dystonic posturing of the right limbs, and partial consciousness
impairment) and severe ideomotor slowing with mixed aphasia; PI: partial improvement, defined as the coexistence of perioral myoclo-
nia, subclinical ictal discharges, and motor aphasia; I: improvement, defined as the persistence of isolated perioral myoclonic jerks and
the improvement of language fluency. Plasma concentrations of D9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabidivarin
(CBDV) were quantified by liquid chromatography tandem mass spectrometry (LC-MS/MS) according to Ferreiros et al. with slight
modifications. After solid phase extraction (SPE), chromatography was performed on KInetex C18 column (50 9 2.1 mm, 2.6 particle
size) with a gradient of 0.01% formic acid in water and 0.01% formic acid in methanol. THC and CBDV were monitored using positive
mode electrospray ionization and multiple reaction monitoring (MRM). The transitions were m/z 315 ? 193 and 287.2 ? 165.2 for
THC and CBDV, respectively. The limit of quantification (LOQ) was 0.5 ng/ml for both analyses. (B) Normalized time-course of the
averaged (mean  SEM) GABA current rundown in oocytes transplanted with hippocampal membranes in control condition (filled
symbol) and after 50 nM CBDV application (empty symbol). Data refer to 30 oocytes, 4 patients. In all experiments the holding poten-
tial was 60 mV. Current amplitude normalized to the first response of rundown protocol. Inset: Representative GABA current traces
in one transplanted oocyte showing the first and sixth response to GABA 500 lM (black bars) before and after 50 nM CBDV application
as indicated. Data refer to 4 TLE patients (4 males, mean age 32.7  9.5 years; mean epilepsy onset 12.7  1 years). All patients had
mainly complex partial seizures resistant to maximal doses of different antiepileptic drugs and had hippocampal sclerosis (HS) with neu-
ronal loss within all hippocampal subfields, including CA1 and CA4 (HS, ILAE type 1). For the clinical part of the study, informed con-
sent was obtained. For the experiments, TLE tissues with HS were provided by Amsterdam University (AMC) and used in accordance
with the Declaration of Helsinki.
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effects. However, it was unmistakably observed that each
time cannabis was withdrawn, focal motor seizures
involving the right hemisoma relapsed after about 4 days
from discontinuation. When the same strain was used for
several months, the patient’s general conditions steadily
improved, in terms of both motor and cognitive perfor-
mances. In particular, periodic neurological examinations
showed an increase in verbal fluency/comprehension and
praxic skills. He was also administered a simplified ver-
sion of the Neuropsychological Assessment Battery for
adolescents with epilepsy recommended by the Italian
League Against Epilepsy (including Wechsler Adult
Intelligence Scale, Trail Making Test, and Wisconsin
Card Sorting Test) and Aachen Aphasia Test, which con-
firmed his improvement. The patient’s participation in
school activities, which had been intended only to reach
socialization goals, dramatically changed, and he could
even graduate thanks to a simplified lesson plan and the
help of a learning support teacher. According to the
patient’s seizure diary, major motor seizures disappeared,
although isolated perioral myoclonic jerks occurred sev-
eral times a day. Weekly/monthly prolonged video EEG
monitoring with polygraphic study documented the dras-
tic reduction of the usual subcontinuous paroxysmal
epileptiform activity over the left frontotemporal regions,
although abundant slow abnormalities intermingled with
spikes/spike-and-waves persisted. During follow-up, no
side effects were reported. In the attempt to find a con-
sistent correlation with the patient’s clinical evolution,
the serum levels of THC, CBD, and CBDV were periodi-
cally measured. Interestingly, when the patient’s
conditions improved, high concentrations of CBDV were
detected in his blood (Fig. 2A). Serum levels of the other
antiepileptic drugs were repeatedly measured as well and
were always within range, without remarkable changes
compared with the levels detected before cannabis
introduction.
From Clinical Cues to
Experimental Approach
The potential mechanisms underlying CBDV clinical
effects are several and only partially known.6,9 Considering
some recent data emphasizing the possible role of GABA-
mediated action of cannabis, we decided to test CBDV
effect on GABAergic transmission in human tissue.10,11
However, because of the unavailability of the patient’s own
surgical specimens (temporal lobe tissue was already fixed
and embedded in paraffin) and the rarity of his pathology,
we performed our experiments on the hippocampal speci-
mens resected from four drug-resistant temporal lobe
epilepsy (TLE) patients (for details, see Fig. 2B) and on
specimens obtained from a single patient affected by RE
(female, 25 years old).
Patients and methods
TLE tissues with hippocampal sclerosis (HS) and RE tis-
sues were transplanted in Xenopus oocytes. Membrane and
oocyte preparation/injection procedures were performed as
previously detailed.8,10 GABA current rundown (I%) was
defined as the decrease, calculated in percentage, of the cur-
rent peak amplitude after six 10-s applications of 500 lM
GABA at 40-s intervals;9 the percentage of the original cur-
rent amplitude remains. Oocytes were incubated with
CBDV (50 nM) for 120–150 min after the control rundown
protocol. For an internal control, other cells were incubated
with oocytes Ringer’s solution8,10 in the same conditions.
All results are given as mean  standard error (SEM). Two
data sets were considered statistically different when
p < 0.05 (analysis of variance [ANOVA] test). All drugs
were purchased from Sigma Italia, with the exception of
GABA (Tocris, Bristol, UK) and CBDV (THC Pharm,
Frankfurt, Germany).
Electrophysiological results
Considering the proven effect of cannabinoids on
GABA-evoked currents11 (IGABA), we focused our attention
on the modulation exerted by CBDV on GABAA-Rs, previ-
ously reported to be impaired in these patients.10 This
impairment was recorded as a strong use-dependent desen-
sitization (i.e., rundown) of the GABAA receptor mediated
currents that was recovered by blocking the protein kinase
C (PKC) pathway.12 In agreement with previous results,10
application of GABA (500 lM) to transplanted oocytes eli-
cited bicuculline-sensitive inward currents (IGABA ampli-
tude range: 10 nA to 100 nA). When oocytes were
injected with hippocampal membranes of TLE patients and
RE tissues, we found a consistent IGABA rundown following
repetitive application of GABA (I% TLE = 45%  12; 49
oocytes; 4 patients; Fig. 2B; I% RE = 49%  7.9; 10
oocytes; for RE, see Fig. S1). In these cells, the simultane-
ous application of CBDV (from 50 nM to 50 lM) and
GABA did not alter the IGABA rundown (data not shown). In
contrast, prolonged exposure to CBDV (from 30 min to
3 h)12 decreased IGABA rundown, with a maximal effect
obtained 2 h after 50 nM CBDV treatment (I% TLE =
65%  11; 35 oocytes; 4 patients, p < 0.05; Fig. 2B; I%
RE = 72%  6.7; 10 oocytes; p < 0.05; see Fig. S1). Con-
centrations lower than 5 nM did not exert effects; at 10 nM
we observed a small, but not statistically significant, effect,
while CBDV doses higher than 50 nM (up to 50 lM) did not
induce a further improvement of rundown (data not shown).
The described effect was not detected in brain tissues
obtained from 4 nonepileptic controls (data not shown).
Because it has been previously shown13 that GABAAR run-
down was affected by levetiracetam (LEV), we performed
experiments incubating oocytes with both CBDV 50 nM
and LEV 1 lM. Our results clearly indicate that the two
compounds did not show a cumulative effect (from I% =
47%  5.2 to 63.5  4.1 for CBDV; from 49%  5.0 to
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66.1  5.3 for CBDV plus LEV; 8 oocytes each set of
experiments).
Interestingly, CBDV effect was not blocked by selective
PKC antagonist GF 109203X 1 lM12 (I% = 60.5%  9.0,
19 oocytes; 4 patients) and by transient receptor potential
vanilloid (TRPV) channel antagonist capsazepine 10 lM9
(see Table S1), but it was blocked by broad spectrum kinase
inhibitor staurosporine13 (from I% = 42  13 to I% =
44  11, 10 oocytes, 2 TLE patients; see Table S1).
Discussion
We report the case of a patient with a probable focal vari-
ant of RE who tried cannabis in addition to his medical ther-
apy. The periodic electroclinical evaluations during
cannabis treatment showed a variable decrease in both sei-
zure frequency and epileptiform paroxysmal activity over
time but, most importantly, a consistent, unambiguous
worsening of the patient’s conditions soon after cannabis
withdrawal. Interestingly, the repeated analyses of cannabi-
noid serum levels revealed that, paralleling electroclinical
improvements, the concentrations of CBDV were always
particularly high, which suggested that CBDV might play a
crucial role and greatly contribute to cannabis anticonvul-
sive effect. As expected, it was not possible to identify a
“threshold efficacy level” for either CBD or CBDV. In addi-
tion, our data did not allow us to exclude that it was not a
single compound but the different molecules combined
together to have the most effective antiepileptic action. This
hypothesis is in accordance with recent in vivo studies test-
ing enriched cannabis extracts, which showed not only that
cannabis anticonvulsant properties are most likely indepen-
dent from THC but also that CBD and CBDV may have an
additive effect, as proved by isobolographic methods.14
Interactions between cannabinoids and the other antiepilep-
tic drugs (AEDs)15 used by the patient (namely, LEV, topi-
ramate, clobazam, clonazepam) could have also influenced
the clinical outcome, either through pharmacodynamic
mechanisms or reciprocal changes in pharmacokinetic prop-
erties. Indeed, although periodic controls did not reveal sig-
nificant alterations in AED concentrations after the
introduction of cannabis, potential interferences with
cannabinoid level, bioavailability, and metabolism cannot
be ruled out at present.
Based on the reported clinical experience and surprising
beneficial effect of cannabis, we tried to better define the
general action of CBDV. In a set of experiments, we showed
a new possible mechanism of action elicited by CBDV on
GABAA current rundown, a well-known phenomenon
described in drug-resistant epileptic patients.10,12 Notably,
we can clearly state that CBDV and LEV did not act in a
synergistic fashion on rundown improvement. In addition,
this effect was not mediated by TRPV channels activity,9
but it was modulated by a kinase or a PKC isoform other
than the PKC a, b1,d, f.13
Although further investigations are needed, these find-
ings may be relevant for future pharmacological develop-
ments. Moreover, considering the specific epileptic
syndrome of our patient and the acknowledged anti-inflam-
matory properties of cannabis, immune-modulating effects
contributing to the clinical improvement should be taken
into consideration.
In conclusion, our case supports the tolerability and
potential efficacy of cannabis in the treatment of drug-resis-
tant epilepsy and highlights the role of CBDV as an
antiepileptic drug. Accordingly, for the first time we pro-
pose GABAA-Rs as a possible new target for CBDV.
The reported clinical experience and the following exper-
imental approach confirm the need for both well-designed
randomized clinical trials (RCTs) and targeted experimental
studies.
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